Research ArticleCardiovascular and Metabolic Risk
HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A. Kushner, Pablo Lapuerta, Darren K. McGuire, Anne L. Peters, Sangeeta Sawhney, Paul Strumph
DOI: 10.2337/dc18-0342 Published 1 September 2018
Thomas Danne
1Department of Diabetes, Endocrinology, and Clinical Research, Children’s and Youth Hospital Auf der Bult, Hannover Medical School, Hannover, Germany
Bertrand Cariou
2L’institut du thorax, Department of Endocrinology, CHU Nantes, CIC 1413, INSERM, Nantes, France
Phillip Banks
3Lexicon Pharmaceuticals, Inc., The Woodlands, TX
Michael Brandle
4Department of Internal Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland
Helmut Brath
5Diabetes Outpatient Clinic, Health Center South, Vienna, Austria
Edward Franek
6Mossakowski Medical Research Center, Polish Academy of Sciences, Warsaw, Poland
Jake A. Kushner
7Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX
Pablo Lapuerta
3Lexicon Pharmaceuticals, Inc., The Woodlands, TX
Darren K. McGuire
8Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX
Anne L. Peters
9University of Southern California Keck School of Medicine, Los Angeles, CA
Sangeeta Sawhney
3Lexicon Pharmaceuticals, Inc., The Woodlands, TX
Paul Strumph
3Lexicon Pharmaceuticals, Inc., The Woodlands, TX